WATCH 2011 Annual Meeting All-Access Right Here

Wednesday, May 26, 2010

Tough Questions

It’s no secret that one of the tough questions in American psychiatry—and at this meeting—is how psychiatrists can interact with the pharmaceutical industry without compromising their integrity or the interests of their patients. Over the weekend, the APA Assembly rejected several proposals that would have provided guidance on which relationships can be problematic and are best avoided. (Full disclosure: I chaired a workgroup appointed by the APA Board that wrote of one the documents that was voted down.) Instead, the Assembly adopted a vague statement that psychiatrists should be aware of their conflicts and manage them, without any guidance on how to do either.


I had two interactions this evening, however, that underscored just how important it is for American psychiatry to provide clearer guidance—and just why that may not be easy to do. On the street outside the Hilton, I was approached by someone who asked if I came to the meeting every year. When I said I did, he wanted to know why there were so many fewer sessions this year. “We used to be able to go to sessions from 7:30 in the morning to 10 at night.” I told him that APA had made a decision to phase out industry-supported symposia, both to protect the objectivity of the program and to reduce APA’s dependence on industry funding. He was puzzled by my response. “I come to get education. [He appeared to be referring to CME credits.] Whether it’s good education or bad education, it’s all education.

Good information or bad, so long as we get CME credits, that’s all that matters? As I was pondering the implications of that interaction, I headed over to one of the ubiquitous receptions, where a prominent member of the APA Assembly came over to talk. She wanted me to know, she said, that she’d thought the report of the workgroup I’d chaired—which she’d voted against—was really quite good. There was just one problem. It had recommended that psychiatrists not give talks when they don’t control the content of their presentations. When physicians give promotional talks for industry, they are handed a slide set created by the company. Our workgroup thought it was inappropriate for a physician to be dispatched to mouth the words written by the company that was signing the check. “I give a lot of those talks,” she told me. “They pay my mortgage. There’s no way that I can stop.” Then she smiled, as though she knew I would understand.

I don’t know, of course, how many psychiatrists will listen to just about anything so long as they get CME credits. Or how many are so dependent on drug company money that they can’t imagine living without it. But for this psychiatrist, it was a troubling evening in the Big Easy.


Paul S. Appelbaum, M.D.
APA former past-president

Dreams sometimes come true

In our lives we all have myriad aspirations, but sadly most times things do not work out. Thankfully, our highly elaborate ego defense mechanisms, including plain denial, exist to protect us from seeing things as they really are. Very few people are accepted to their dream schools, marry their dream partners, get their dream jobs, live in their dream homes, or live their dream lives. Maturity consists of accepting both our intrinsic limitations and those of our circumstances. Isn’t it a shock when as we grow up we realize that our parents are also (very!) limited and that we are essentially on our own? Yet, in spite of checks imposed by reality, we keep dreaming.

When Alan Schatzberg invited me to be Chair of the Scientific Program Committee of the APA over one year ago, I accepted that challenge with joy. And almost immediately I started dreaming. I dreamed of a national and international meeting that would be a true one-stop shop for the field of psychiatry. Over the last couple of decades our field evolved in such a way that different groups focused increasingly more on their own networks, organizations, and meetings. Our colleagues started to prioritize more and more their focused meetings, such as those of the Academy of Child and Adolescent Psychiatry, American College of Neuropsychopharmacology, and Society of Biological Psychiatry, among others. The feeling was that the APA Annual Meeting was too busy, too chaotic, and not the place to present the most cutting edge content. As the meeting was based on submissions, we were at the mercy of what came to us.

My dream as I was given the unique opportunity to lead the Scientific Program Committee was to revamp the annual meeting as a one-stop shop to completely fulfill the needs of a variety of constituencies: those who wanted to see the latest discoveries and advances, those who wanted to meet the leaders in our field, those who wanted the best evidence-based clinical data to inform their practice, and those who sought to learn specific topics in CME courses. It is time-consuming and expensive to travel. Why do our members need to do things piecemeal, attending several meetings, when their could all be accomplished at the APA?

The strategy over the course of the past year then became to invite top speakers to the Annual Meeting. We made a strategic plan to invite approximately 50% of the content. Then, in September 2009 I moved halfway around the world, to Australia, to become Director of the John Curtin School of Medical Research at the Australian National University, which is Australia’s national medical research institute. Should I then give up the dream? Of course not! That is why the internet and old fashioned phones exist. We also added Don Hilty as a co-chair of the Scientific Program Committee to make this long distance endeavor possible. But would this really work?

As background, I am very fortunate that another old dream of mine had come true. Those who specialize in addiction know that there is nothing like intermittent reinforcement to really hook someone. My old dream that started in the 90’s was to create a new journal that was conceptually novel, and that would integrate basic and clinical science and would rapidly rise to the top. Molecular Psychiatry, that I founded in 1996 and continue to edit to this day, achieved its editorial goals and it is now the second most cited psychiatric journal worldwide (Impact Factor of 12.5). I make all reviewer assignments and all editorial decisions for all our papers. In 2010 the number of submission is expected to reach 1,000. Due to this demanding “hobby” I am very aware of the latest breakthroughs in psychiatry and in these last 15 years I developed excellent working relationships with the leaders in the field. So, from Australia, I tapped my network of contacts worldwide and was able to invite vast numbers of national and international experts to the meeting. It worked! As the science of psychiatry rapidly advances and starts to impact on practice my bet was that our members would be attracted to the cutting edge. Our standing room only sessions proved that my instinct was right.

As our Annual Meeting rapidly reaches its end, I see my dream come true. This meeting has been a very successful one-stop shop for any psychiatrist of any orientation. All the key areas were covered – by top experts. Sessions of direct clinical relevance were as successful as those that presented the latest developments on scientific basis of psychiatry. Courses were a big hit (thanks, Michele Pato). The incredible staff of the APA and the very keen and dedicated members of our Scientific Program Committee deserve to be congratulated for their tireless efforts. Don Hilty was a superb co-chair. Without them we wouldn’t have been able to put together such a fantastic meeting. Contradicting John Lennon, who famously stated in his song “God” that “the dream is over,” I am delighted that my dream is still alive as the 2010 Annual Meeting is ongoing. Importantly, I am hopeful that the dream will continue to live on through future APA meetings.











Julio Licinio, M.D.
Co-chair
Scientific Program Committee
American Psychiatric Association
Director
John Curtin School of Medical Research
The Australian National University
Canberra, Australia

Editor
Molecular Psychiatry
Nature Publishing Group
London and New York City

Tuesday, May 25, 2010

Depression in a High-Achieiving Athlete: An Encounter With Terry Bradshaw

In the mid '80’s, as a sport psychiatrist, I was fortunate enough to interview Terry Bradshaw for a cable TV show. The topic was “Why Super Bowl Champs Can’t Repeat." His Steelers of the '70’s had made that look easy, but at the time I did the interview, no other NFL team had been able to win the Super Bowl in successive seasons since.

Terry took the time to talk to me from the barn of his farm in Louisiana. He was accessible and generous with his time. He seemed to enjoy the fact that I was a psychiatrist and kidded me about it. His comments about the conservative mindset that can go along with defending something you’ve won, versus the attacking mindset when you are trying to take something from someone struck me as very insightful and intelligent.

Little did I realize then that the weight of defending all those championships probably laid more heavily on Terry’s shoulders than most. As he later publicly acknowledged, he had suffered from depression for years while playing. He described breaking into tears and sweating profusely after a game, not realizing what the problem was. Because of the prevailing myth that high-level athletes would not become depressed “like regular people,” and the stigma against admitting it if it did occur, none of his teammates, coaches or staff recognized that Terry had an illness. Terry became even more melancholy after retirement (a common phenomenon), sought psychotherapy, and was finally properly diagnosed and prescribed paroxetine, which helped him greatly. He then went on to talk about his depression and treatment publicly, becoming the first very high-profile athlete to do so.

Soon after Terry’s disclosure, the Hall of Fame jockey, Julie Krone, and the Olympic diver Wendy Williams came forward, notably at International Society for Sport Psychiatry Symposia here at the APA convention, which I had the pleasure to chair. Both Julie and Wendy openly discussed the fact that they had taken SSRI’s for anxiety and depressive disorders while competing. They shared with us that the SSRI’s had helped their conditions greatly, and had not negatively impacted their performance, though the illnesses certainly had.
Julie continued to use SSRI’s when riding and became an information source for jockeys and other athletes who were struggling with emotional disorders. Suddenly, there was less stigma to being prescribed a psychiatric medication, or to receiving psychotherapy while competing, and many other well-known athletes have since stepped forward to share their stories.

In my practice, these narratives had made it easier for my athlete patients to try a medication when it is offered. Another welcome benefit is that my non-athlete patients are more open to trying an antidepressant as well. As we discuss side effects, I mention that if Terry Bradshaw can take an SSRI and Julie Krone can compete on it, the medication must be fairly well tolerated, right?

Ronald L. Kamm, M.D.
Distinguished Life Fellow, American Psychiatric Association
Past-President, International Society for Sport Psychiatry

Eating Disorders, DSM5 at the APA

One always has a dilemma at the APA Annual meeting, and I call this the embarrassment of riches problem: there is so much going on that it is hard to choose what to attend. I try to attend a few talks outside my main interests so that I can keep up in other areas. But so much is going on, how does one choose? Sometimes I’ll choose to listen to a well-known expert, and other times I’ll choose a workshop or symposium based on a provocative title. Not infrequently, I will conclude that I made the wrong choice, and will leave and seek out something else. And sometimes I will enter a room almost at random because I want to rest.
I had reviewed the agenda and decided to listen to Kathy Halmi talk about eating disorders. She actually trained at my program (Iowa), and while she left before I got there, we have interacted a number of times, and I highly respect her. She has a no-nonsense way of thinking and presenting material that I like, and I guess what I learned was that--according to her--a core problem of anorexic patients is their sense of ineffectiveness. I guess I had never thought of that before. She provided a review of treatments, and all I can say is that more work is desperately needed.

That afternoon, I sat in on a DSM5 update and listened to Joel Dimsdale talk about proposed changes to the somatoform disorders. Now I have a beef about this: somatization disorder is probably one of the best validated disorders, though is underutilized. The diagnosis stems from Briquet’s syndrome, and was defined and validated by the Washington University group in the 1950’s. I ask: why are we even thinking about removing a valid diagnosis from the manual just because it is underutilized? I then sat in on a friend’s talk (Pinhas Dannon) about the neuropsychology of pathological gambling. He contends that these patients are not impulsive, and hence that pathological gambling is a behavioral addiction. The problem I have with this is that I think they are impulsive, and that’s what I see in my samples. (This is a research interest of mine – yes, we have loads of gambling in Iowa).

Donald W. Black, MD
University of Iowa

Comparative Effectiveness of Psychotropic Drugs

"What Can We Learn From Practical Clinical Trials?" presented data from the latest large practical trials in mood disorders and schizophrenia. Among the highlights were the following. In the United Kingdom’s Balance Study it was found that for bipolar disorder, the combination of the medications lithium and valproate was more effective than valproate alone and that lithium was nonsignificantly better than valproate in preventing relapses and maintaining stability. In addition, the NIMH CATIE study group or Schizophrenia Trials Network reported on the METS Study and found that metformin 2 grams/day produced a 3 kg weight loss in patients with antipsychotic induced weight gain. Other studies described important important results addressing fundamental questions in the treatment of psychotic and mood disorders.

Jeffrey A. Lieberman, M.D.
Chairman, Department of Psychiatry, College of Physicians and Surgeons, Columbia University Director, New York State Psychiatric Institute Director, Lieber Center for Schizophrenia Research Psychiatrist-in-Chief @ New York Presbyterian Hospital & Columbia University Medical Center

Softshell crab, café au lait and cognitive behavioral neurology …

At mid-day Monday, New Orleans was her classic self with 92 degree heat and 100% humidity. Along with the famed softshell po’ boys and café au lait, did you know that New Orleans is also known for its outstanding excellence in cognitive and behavioral neurology? Yes, at LSU Health Science Center, renowned Cognitive and Behavioral Neurology is headed by New Orleans native Anne L. Foundas MD. As the author of more than 80 refereed papers and PI on numerous grants, Dr. Foundas is recognized as a leader in the rapidly expanding interdisciplinary field of Cognitive Neurosciences. She currently serves as Professor of Neurology and Vice-Chair of Clinical Research in the Department of Neurology, Louisiana State University Health Sciences Center in New Orleans.

Not only is Dr. Foundas and accomplished researcher and author, she is also an extraordinary clinician and award-winning and engaging teacher. The APA is quite fortunate as Dr. Foundas presented at the Annual Meeting on Tuesday, May 25, Advances in Medicine 4 Aging and Dementia: An Update on Neuroscience and Brain Imaging.

While at the Annual Meeting, be sure not to miss one of New Orleans’ finest!

In her words, Dr. Foundas describes her work:

Cognitive Neuroscience is being driven by dramatic advances in neuroimaging and neurophysiologic methods. Anatomical details of the brain can be reconstructed using structural MRI methodologies. Cognitive functions, such as memory and language, can be studied by analyzing subtle, task-related changes in blood flow using functional MRI paradigms. The timing of neural activity can be precisely mapped using cortical event-related potentials (ERP) which can be co-registered with brain images derived from structural and functional MRI. Cerebral ischemia can be studied with diffusion-perfusion weighted imaging, and metabolic studies can be conducted with MR spectroscopy. Motor and cognitive neural systems can be studied using transcranial magnetic stimulation (TMS) methods. In this way, the precise anatomy, function, timing, and physiology of neural events can be studied in humans in vivo. We have utilized these state-of-the-art MRI and neurophysiological methods to study complex cognitive operations in healthy individuals, and then we have applied these methods to study clinical populations including: developmental stuttering, stroke, dementia, and epilepsy.
Our long-term goal is to develop targeted treatment strategies based on the knowledge that we gain from these basic neuroscience studies. Translational research programs are being developed to bridge basic and clinical neuroscience research. Targeted program development includes studies of: development and aging, stress and depression, stroke and neuroplasticity, and epilepsy.

Josepha A. Cheong, MD
Member, Scientific Program Committee

Career, Leadership & Mentorship luncheon/Forum

The first of what we hope would become an APA ritual/tradition took place in New Orleans, on Sunday, May 23rd, 2010 during our annual APA scientific meeting. It was convened by Drs. Gary Weinstein & Eliot Sorel with several MITs & ECPs participating.

We heard thought-provoking presentations from Dr. Steven Koh about the mentorship initiative he started in San Diego, California, complemented by a presentation from Dr. Hind Benjelloun about the Career & Leadership, now Career, Leadership & Membership. This initiative was started three years ago by the Washington Psychiatric Society with a grant from Area III; it was expanded to the New Jersey District Branch this spring and is available to others upon request.

The luncheon/Forum also featured discussions of the APA Assembly Leadership Training Manual, which was developed by the APA Assembly’s Leadership Training Workgroup (LTWG) and will soon be available on APA’s website and could be of value in starting such programs nationwide.

The group intends to develop a Career, Leadership & Mentorship (CLM) workshop for next year’s annual meeting as well as convene as a CLM Forum at that time. A CLM workshop is currently being planned for the XX World Congress of Social Psychiatry in Marrakech, Morocco in October 2010.

Eliot Sorel,MD, Chairman, APA Assembly LTWG
Founder, WPS, Career & Leadership
May 23, 2010